These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38444390)

  • 1. Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies.
    Aertker KMJ; Pilvankar MR; Prass TM; Blech M; Higel F; Kasturirangan S
    MAbs; 2024; 16(1):2318817. PubMed ID: 38444390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.
    Datta-Mannan A; Brown R; Key S; Cain P; Feng Y
    Antibodies (Basel); 2021 Dec; 11(1):. PubMed ID: 35076469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method.
    Müller T; Tasser C; Tesar M; Fucek I; Schniegler-Mattox U; Koch J; Ellwanger K
    MAbs; 2023; 15(1):2245519. PubMed ID: 37599441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.
    Datta-Mannan A; Croy JE; Schirtzinger L; Torgerson S; Breyer M; Wroblewski VJ
    MAbs; 2016 Jul; 8(5):969-82. PubMed ID: 27111637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
    Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
    MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
    Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of bispecific antibodies by structure-guided redesign of IgG constant regions.
    Iwasaki YW; Tharakaraman K; Subramanian V; Khongmanee A; Hatas A; Fleischer E; Rurak TT; Ngok-Ngam P; Tit-Oon P; Ruchirawat M; Satayavivad J; Fuangthong M; Sasisekharan R
    Front Immunol; 2022; 13():1063002. PubMed ID: 36703993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
    Dong J; Sereno A; Snyder WB; Miller BR; Tamraz S; Doern A; Favis M; Wu X; Tran H; Langley E; Joseph I; Boccia A; Kelly R; Wortham K; Wang Q; Berquist L; Huang F; Gao SX; Zhang Y; Lugovskoy A; Martin S; Gouvis H; Berkowitz S; Chiang G; Reff M; Glaser SM; Hariharan K; Demarest SJ
    J Biol Chem; 2011 Feb; 286(6):4703-17. PubMed ID: 21123183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells.
    Watanabe Y; Tanabe A; Hamakubo T; Nagatoishi S; Tsumoto K
    J Biochem; 2021 Oct; 170(2):307-315. PubMed ID: 33844018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
    Ng CM; Fielder PJ; Jin J; Deng R
    AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.
    Zwolak A; Armstrong AA; Tam SH; Pardinas JR; Goulet DR; Zheng S; Brosnan K; Emmell E; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017; 9(8):1306-1316. PubMed ID: 28898162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
    Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
    MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.